Aridis Pharmaceuticals (NASDAQ:ARDS – Get Free Report) and Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.
Valuation and Earnings
This table compares Aridis Pharmaceuticals and Cartesian Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aridis Pharmaceuticals | $3.09 million | 1.02 | -$30.37 million | ($0.16) | -0.40 |
| Cartesian Therapeutics | $26.00 million | 16.47 | -$219.71 million | N/A | N/A |
Aridis Pharmaceuticals has higher earnings, but lower revenue than Cartesian Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Aridis Pharmaceuticals | -5.11% | N/A | -20.47% |
| Cartesian Therapeutics | -983.93% | -58.21% | -18.77% |
Risk & Volatility
Aridis Pharmaceuticals has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
Insider and Institutional Ownership
9.7% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 61.1% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Aridis Pharmaceuticals and Cartesian Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aridis Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| Cartesian Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
Aridis Pharmaceuticals presently has a consensus price target of $2.00, indicating a potential upside of 3,000.78%. Cartesian Therapeutics has a consensus price target of $45.00, indicating a potential upside of 87.03%. Given Aridis Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Aridis Pharmaceuticals is more favorable than Cartesian Therapeutics.
Summary
Cartesian Therapeutics beats Aridis Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
